- Citations, last 5 years
- 356.5k
- Works, last 5 years
- 25.4k
- h-index
- 1,797
- Scientists listed
- 655
- Grants since 2016
- 3 144
Grants received
2018–2023 · research · R01
Hematopoietic stem cell gene therapy for infantile neuronal ceroid lipofuscinosis
Alessandra Biffi · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2020 · career development · K01
Selectivity for Kinesin-driven Transport of Axonal RNA Granules
Yusuke Fukuda · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2024 · cooperative agreement · U54
The Center for Therapeutic Targeting of EWS-oncoproteins
Scott A Armstrong · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · research · R37
Molecular origins and evolution to chemoresistance in germ cell tumors
Eliezer M Van Allen · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2020 · research · R21
Study of Plasma Next Generation Sequencing for Remote Assessment, Characterization, Evaluation of Patients with ALK Drug Resistance (SPACEWALK)
Geoffrey Raymond Oxnard · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2021 · research · R21
A Palliative Care mHealth Intervention to Support Advanced Cancer Patients and Oncology Providers in Opioid Management
Andrea C Enzinger · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2022 · career development · K00
Metabolically active macrophages: a novel link between obesity and triple negative breast cancer
Payal Tiwari · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2020 · research · R21
A Palliative Care mHealth Intervention to Support Advanced Cancer Patients and Oncology Providers in Opioid Management
Andrea C Enzinger · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · research · R01
Integrative Somatic and Germline Computational Biology to Redefine Clinical Actionability in Solid Tumors
Eliezer M Van Allen · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2024 · grant · DP1
Identification of Novel Protein Kinases Dependent on Phosphocreatine Rather than ATP
Bruce M. Spiegelman · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · research · R01
Hematopoietic stem cell gene therapy for infantile neuronal ceroid lipofuscinosis
Alessandra Biffi · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2021 · program · P20
Precision Interception of Aggressive Prostate Cancer in African American Men
Timothy R Rebbeck · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · cooperative agreement · U2C
The Cellular Geography of Therapeutic Resistance in Cancer
Bruce E. Johnson · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · research · R01
EZH2 in cancer biology and novel inhibitors
Jun Qi · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2022 · research · R01
Advanced computational methods in analyzing high-throughput sequencing data
Heng Li · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2022 · grant · PCRP
RET Kinase Signaling as a Key Switch Toward the Neuroendocrine Phenotype
Leigh Ellis · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2018–2023 · research · R37
Targeting blastic plasmacytoid dendritic cell neoplasm (BPDCN)
Andrew A Lane · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · research · R01
The Role of RHOA in Diffuse Gastric Cancer
Adam Joel Bass · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2021 · research · R21
Identifying PTSD in Young Adult Cancer Survivors in the DSM-5 Era: Are Newly Revised PRO Measures Accurate Compared to a Structured Diagnostic Interview?
Christopher John Recklitis · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2025 · research · R35
Development of Combination Therapies to Delay/Prevent Acquired Drug Resistance
Pasi A Janne · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018 · career development · K01
The Role of PARP3 in Telomere Regulation
Tovah Day · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2024 · cooperative agreement · U54
The Center for Synovial Sarcoma Biology and Therapeutics
Cigall Kadoch · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · cooperative agreement · U01
Molecular and immune drivers of immunotherapy responsiveness in prostate cancer
Lawrence Fong · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · cooperative agreement · U2C
The Cellular Geography of Therapeutic Resistance in Cancer
Bruce E. Johnson · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · grant · DP1
Identification of Novel Protein Kinases Dependent on Phosphocreatine Rather than ATP
Bruce M. Spiegelman · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · research · R01
Effects of marijuana use on inflammation and vascular injury in adults with HIV infection
Dana H. Gabuzda · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2019 · program · P01
Comprehensive Dissection of the CLL Genome and Phenome to Improve Patient Outcomes
Catherine Ju-Ying Wu · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2025 · research · R35
Development of Combination Therapies to Delay/Prevent Acquired Drug Resistance
Pasi A Janne · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2020 · fellowship · F31
The Discovery and Optimization of Alternatives to ATP-Competitive ALK Inhibitors
Chelsea Elizabeth Powell · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2022 · career development · K00
The Role of E2F2 in HER2 Positive Breast Cancer
Jonathan Rennhack · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · research · R01
Immunotherapeutic responses to neoantigens in head and neck cancer
Ravindra Uppaluri · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · research · R01
Resistance and Sensitivity to MET Inhibitors in Lung Cancer
Pasi A Janne · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · research · R01
Effects of marijuana use on inflammation and vascular injury in adults with HIV infection
Dana H. Gabuzda · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · career development · K08
Targeting casein kinase 1-alpha for cancer therapy
Steven Muntean Corsello · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · research · R01
Degrading therapeutically important kinases using small molecules
Eric Sebastian Fischer · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · research · R01
KDM5 histone lysine demethylases as potential novel myeloid tumor suppressors
Julie-Aurore Losman · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · research · R01
EZH2 in cancer biology and novel inhibitors
Jun Qi · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · research · R01
Tumor and host markers of clinical outcomes after MIBG therapy in neuroblastoma
Rochelle Bagatell · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2025 · research · R35
Development of Combination Therapies to Delay/Prevent Acquired Drug Resistance
Pasi A Janne · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2021 · research · R01
Comprehensive minimal residual disease tracking in cancer
G. Mike Makrigiorgos · Dana-Farber Cancer Institute · funded by National Institutes of Health
